BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 22922424)

  • 21. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.
    Schneller D; Machat G; Sousek A; Proell V; van Zijl F; Zulehner G; Huber H; Mair M; Muellner MK; Nijman SM; Eferl R; Moriggl R; Mikulits W
    Hepatology; 2011 Jul; 54(1):164-72. PubMed ID: 21452288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
    BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
    Yan J; Tan C; Gu F; Jiang J; Xu M; Huang X; Dai Z; Wang Z; Fan J; Zhou J
    Liver Transpl; 2013 May; 19(5):507-20. PubMed ID: 23408515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.
    Li Y; Chen L; Chan TH; Liu M; Kong KL; Qiu JL; Li Y; Yuan YF; Guan XY
    Gastroenterology; 2013 Jan; 144(1):179-191.e4. PubMed ID: 23022495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
    Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
    Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Zhu XD; Sun HC; Xu HX; Kong LQ; Chai ZT; Lu L; Zhang JB; Gao DM; Wang WQ; Zhang W; Zhuang PY; Wu WZ; Wang L; Tang ZY
    Angiogenesis; 2013 Oct; 16(4):809-20. PubMed ID: 23716000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.
    Li Y; Tang Y; Ye L; Liu B; Liu K; Chen J; Xue Q
    J Cancer Res Clin Oncol; 2003 Jan; 129(1):43-51. PubMed ID: 12618900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.
    Ma W; Wong CC; Tung EK; Wong CM; Ng IO
    Hepatology; 2013 Jan; 57(1):152-61. PubMed ID: 22829315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY; Lin CS; Tai WT; Hsieh CY; Shiau CW; Cheng AL; Chen KF
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):456-62. PubMed ID: 23474115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.